Oscotec Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Nov 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6H)-one hydrochloride and method for preparing same (US 11,731,969) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Jun 15, 2027The maintenance fee for Substituted Pyrimidine Compounds and Their Use as Syk Inhibitors (US 9,212,178) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,879,835 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives In force · High confidence | In force | High confidence | |
| US 8,629,132 | Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,871,778 | Substituted pyrimidine compounds and their use as SYK inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,877,763 | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,212,178 | Substituted Pyrimidine Compounds and Their Use as Syk Inhibitors In force · High confidence | In force | High confidence | |
| US 11,731,969 | Crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6H)-one hydrochloride and method for preparing same In force · From the USPTO record | In force | From the USPTO record | |
| US 12,350,272 | Pyridopyrimidinone derivatives for use as AXL inhibitors In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 7: 1 patent in force now held by others · 8 lapsed for an unpaid fee · 2 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded